独家直击！苹果盘中市值超越微软：人工智能憧憬助力反弹

苹果盘中市值超越微软：人工智能憧憬助力反弹

北京 - 2024年6月13日，苹果（AAPL）股价周三盘中上涨2.2%，至211.75美元/股，市值达到3.25万亿美元，首次超越微软（MSFT）成为全球市值最大的上市公司。

苹果市值超越微软，主要得益于以下几个因素：

• 投资者对苹果人工智能业务的看好。苹果在人工智能领域布局多年，拥有领先的技术和人才。近期，苹果发布了多款搭载人工智能芯片的新品，市场反应热烈。投资者预期，苹果的人工智能业务将取得强劲增长，推动公司股价上涨。
• 美国股市整体走强。近期，美国股市整体走强，科技股表现尤为突出。苹果作为科技股的代表，也受到市场追捧。
• 微软股价近期有所回落。微软股价近期有所回落，这为苹果超越微软提供了机会。

苹果市值超越微软，是全球科技产业格局变化的一个重要标志。苹果作为一家以硬件产品为主的科技公司，能够在人工智能时代保持领先地位，具有重要的意义。

值得注意的是，苹果和微软都是全球科技巨头，两家公司在市值上的竞争一直非常激烈。此次苹果超越微软，只是暂时的。未来，两家公司在市值上的竞争还将继续。

总体而言，苹果市值超越微软，反映了市场对苹果未来发展前景的看好。未来，苹果能否继续保持领先地位，值得市场关注。

附赠：

• 苹果官网：https://www.apple.com/
• 微软官网：https://www.microsoft.com/

通过此次新闻稿的撰写，我更加了解了苹果市值超越微软的背景和原因，以及对全球科技产业格局的影响。相信随着科技的不断进步和创新的不断涌现，全球科技产业将迎来更加精彩的发展篇章。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.